{"id":"bevacizumab-avastin","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Hypertension"},{"rate":"15–25%","effect":"Proteinuria"},{"rate":"5–10%","effect":"Hemorrhage (including severe/fatal)"},{"rate":"5–10%","effect":"Thromboembolism"},{"rate":"1–2%","effect":"Gastrointestinal perforation"},{"rate":"2–5%","effect":"Wound healing complications"},{"rate":"15–20%","effect":"Fatigue"},{"rate":"10–15%","effect":"Diarrhea"},{"rate":"10–15%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to circulating VEGF, bevacizumab inhibits angiogenesis—the formation of new blood vessels that supply oxygen and nutrients to tumors. This starves cancer cells of their blood supply, slowing or stopping tumor growth. It is often combined with chemotherapy to enhance anti-tumor effects.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:25.940Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"},{"name":"Metastatic non-small cell lung cancer (in combination with chemotherapy)"},{"name":"Metastatic breast cancer (in combination with paclitaxel)"},{"name":"Glioblastoma (recurrent)"},{"name":"Metastatic renal cell carcinoma (in combination with interferon-alpha)"},{"name":"Persistent, recurrent, or metastatic cervical cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT04404881","phase":"PHASE2","title":"Bevacizumab In Hereditary Hemorrhagic Telangiectasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2020-11-23","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":33},{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT05468359","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-11-07","conditions":"Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor","enrollment":64},{"nctId":"NCT03786081","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2019-02-27","conditions":"Cervical Cancer","enrollment":214},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT05116189","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-12-13","conditions":"Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms","enrollment":643},{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":"Ovarian Cancer","enrollment":582},{"nctId":"NCT06083844","phase":"PHASE2","title":"Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-12-12","conditions":"Ovarian Cancer","enrollment":20},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06787612","phase":"PHASE2","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-05-28","conditions":"Ovarian Cancer","enrollment":220},{"nctId":"NCT06061809","phase":"PHASE2","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-08-07","conditions":"Glioblastoma","enrollment":34},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT05601973","phase":"PHASE2","title":"Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2023-03-27","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT00826540","phase":"PHASE2","title":"Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":83},{"nctId":"NCT05584670","phase":"PHASE1, PHASE2","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-11-29","conditions":"Solid Tumor","enrollment":542},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT07317414","phase":"PHASE2","title":"β-alanine in the Treatment of Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-24","conditions":"Hepatocellular Carcinoma","enrollment":158},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT07244705","phase":"PHASE1, PHASE2","title":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","status":"RECRUITING","sponsor":"Anbogen Therapeutics, Inc.","startDate":"2025-11","conditions":"Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)","enrollment":66},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT05440708","phase":"PHASE1, PHASE2","title":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tvardi Therapeutics, Incorporated","startDate":"2023-03-23","conditions":"Hepatocellular Carcinoma","enrollment":178},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT05620771","phase":"PHASE2","title":"Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk","status":"SUSPENDED","sponsor":"Northwestern University","startDate":"2022-11-30","conditions":"Hepatocellular Carcinoma","enrollment":84},{"nctId":"NCT05446870","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-25","conditions":"High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma","enrollment":160},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT01295112","phase":"PHASE2, PHASE3","title":"Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2011-05","conditions":"Non-Ischemic Central Retinal Vein Occlusion","enrollment":68},{"nctId":"NCT05104567","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-12-09","conditions":"Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma","enrollment":138},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03275506","phase":"PHASE2","title":"PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-02-26","conditions":"Ovarian Cancer Stage IV","enrollment":91},{"nctId":"NCT03149575","phase":"PHASE3","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","status":"TERMINATED","sponsor":"DelMar Pharmaceuticals, Inc.","startDate":"2017-10-27","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":2},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT03227263","phase":"PHASE3","title":"BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-09-28","conditions":"Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic","enrollment":24},{"nctId":"NCT06510582","phase":"PHASE1, PHASE2","title":"Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection","status":"RECRUITING","sponsor":"The Cooper Health System","startDate":"2024-06-17","conditions":"Chronic Subdural Hematoma","enrollment":140},{"nctId":"NCT05330429","phase":"PHASE2","title":"Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-08","conditions":"Metastatic Colorectal Cancer","enrollment":77},{"nctId":"NCT03390686","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2019-11-15","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":650},{"nctId":"NCT00696592","phase":"PHASE2","title":"Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration","status":"WITHDRAWN","sponsor":"University of Padova","startDate":"2007-01-31","conditions":"Neovascular Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT04512430","phase":"PHASE2","title":"Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients","status":"TERMINATED","sponsor":"Fundación GECP","startDate":"2020-12-02","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":4},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT01903330","phase":"PHASE2","title":"ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2014-03","conditions":"Glioblastoma, Gliosarcoma","enrollment":84},{"nctId":"NCT03829410","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2019-06-24","conditions":"Metastatic Colorectal Cancer, KRAS Gene Mutation","enrollment":68},{"nctId":"NCT06190093","phase":"PHASE3","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2024-01-24","conditions":"Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration","enrollment":400},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT01220154","phase":"PHASE1","title":"Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer","status":"COMPLETED","sponsor":"David O'Malley","startDate":"2011-04-28","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":9},{"nctId":"NCT06232902","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Tumor","enrollment":84},{"nctId":"NCT06558227","phase":"PHASE2","title":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-10-24","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT02754882","phase":"PHASE3","title":"A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2016-07-05","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":763},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT03390673","phase":"PHASE1","title":"To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Prestige Biopharma Limited","startDate":"2018-09-19","conditions":"Healthy Volunteers","enrollment":119},{"nctId":"NCT06496971","phase":"PHASE3","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","status":"RECRUITING","sponsor":"NaviFUS Corporation","startDate":"2024-11-08","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult","enrollment":32},{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT06313268","phase":"","title":"Safety of Effivia®, a Bevacizumab Biosimilar","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2022-08-11","conditions":"Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer","enrollment":83},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT06099418","phase":"PHASE2","title":"Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.","status":"WITHDRAWN","sponsor":"Nykode Therapeutics ASA","startDate":"2024-04-18","conditions":"HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer","enrollment":""},{"nctId":"NCT06590844","phase":"PHASE4","title":"\"cindilizumab + Bevacizumab + Coenzyme I for Injection\" in Unresectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2023-12-19","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":37},{"nctId":"NCT04408989","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2021-01-11","conditions":"Healthy Volunteers","enrollment":114},{"nctId":"NCT05654454","phase":"PHASE3","title":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Mabscale, LLC","startDate":"2023-05-31","conditions":"Non-Small Cell Lung Cancer","enrollment":620},{"nctId":"NCT05705791","phase":"NA","title":"Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-02-07","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04408118","phase":"PHASE2","title":"First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-05","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer","enrollment":100},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT01763645","phase":"PHASE3","title":"A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Biocad","startDate":"2012-10","conditions":"Non-small Cell Lung Cancer","enrollment":353},{"nctId":"NCT04238663","phase":"PHASE1","title":"Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2019-09-24","conditions":"Healthy Volunteers","enrollment":115},{"nctId":"NCT02313272","phase":"PHASE1","title":"Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2015-07-28","conditions":"Malignant Glioma","enrollment":32},{"nctId":"NCT04446416","phase":"NA","title":"Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients","status":"COMPLETED","sponsor":"NaviFUS Corporation","startDate":"2020-07-21","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioma","enrollment":6},{"nctId":"NCT00667342","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-06-03","conditions":"Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone","enrollment":43},{"nctId":"NCT03919448","phase":"PHASE1","title":"A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab","status":"COMPLETED","sponsor":"Laboratorios Richmond S.A.C.I.F.","startDate":"2019-04-01","conditions":"Pharmacokinetics, Safety Issues","enrollment":112},{"nctId":"NCT01468623","phase":"PHASE4","title":"Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6","status":"TERMINATED","sponsor":"Myriad Genetic Laboratories, Inc.","startDate":"2011-09","conditions":"Colorectal Cancer, Metastatic","enrollment":51},{"nctId":"NCT01079780","phase":"PHASE2","title":"Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2011-01-18","conditions":"Colorectal Cancer","enrollment":136},{"nctId":"NCT05431582","phase":"PHASE1","title":"Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-14","conditions":"Tumors, Ovarian Cancer, Breast Cancer","enrollment":""},{"nctId":"NCT05797883","phase":"PHASE2","title":"FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-08-01","conditions":"Unresectable or Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03063762","phase":"PHASE1","title":"Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-20","conditions":"Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT01745757","phase":"","title":"Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-06","conditions":"Metastatic, Breast Cancer","enrollment":510},{"nctId":"NCT04822818","phase":"PHASE3","title":"EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-17","conditions":"Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases","enrollment":96},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT00467142","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-01-23","conditions":"Colorectal Cancer","enrollment":62},{"nctId":"NCT04812977","phase":"NA","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hayatabad Medical Complex","startDate":"2018-06-10","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":30},{"nctId":"NCT05502991","phase":"PHASE2","title":"Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Provincial People's Hospital","startDate":"2022-12-11","conditions":"Glioblastoma","enrollment":60},{"nctId":"NCT05512351","phase":"PHASE2","title":"Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma","status":"RECRUITING","sponsor":"Henan Provincial People's Hospital","startDate":"2022-12-23","conditions":"Oligodendroglioma","enrollment":80},{"nctId":"NCT05476341","phase":"PHASE1","title":"A Phase I Clinical Trial of Bevacizumab Injection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2017-04-06","conditions":"Rectal Cancer, Lung Cancer, Ovarian Cancer","enrollment":98},{"nctId":"NCT05427305","phase":"PHASE3","title":"TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2017-10-20","conditions":"Efficacy","enrollment":549},{"nctId":"NCT02985619","phase":"PHASE2, PHASE3","title":"Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-07-21","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT05378867","phase":"PHASE3","title":"A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2022-08-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":126},{"nctId":"NCT05366062","phase":"PHASE2","title":"ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2022-07-01","conditions":"Glioma, Malignant","enrollment":28},{"nctId":"NCT00887536","phase":"PHASE3","title":"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1613},{"nctId":"NCT02469987","phase":"PHASE1","title":"Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-04","conditions":"Healthy","enrollment":111},{"nctId":"NCT04633564","phase":"PHASE3","title":"MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2017-01-21","conditions":"NSCLC Stage IV","enrollment":671},{"nctId":"NCT02810457","phase":"PHASE3","title":"Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Centus Biotherapeutics Limited","startDate":"2016-09-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":731},{"nctId":"NCT05169801","phase":"PHASE3","title":"To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-01-25","conditions":"Non-small Cell Lung Cancer(NSCLC)","enrollment":520},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin®","Avastin","Anti-VEGF monoclonal antibody","rhuMAb-VEGF"],"phase":"marketed","status":"active","brandName":"Bevacizumab (Avastin®)","genericName":"Bevacizumab (Avastin®)","companyName":"Hanny Al-Samkari, MD","companyId":"hanny-al-samkari-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors need to grow. Used for Metastatic colorectal cancer (in combination with chemotherapy), Metastatic non-small cell lung cancer (in combination with chemotherapy), Metastatic breast cancer (in combination with paclitaxel).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}